With new unbiased analysis features and an easy-to-use interface, the CytoML 5.2 uses batch processing to engage a range of parameters used simultaneously for better data representation.
Aigenpulse launched the CytoML 5.2, an update to its CytoML Experiment Suite, an automated machine learning solution aimed at streamlining and automating cytometry analysis at scale and replacing manual gating processes.
The new addition works to automate every stage in the flow cytometry data lifecycle by increasing the throughput of data processing and analytics by as much as 600%, increasing the accuracy, reproducibility, and quality of flow cytometry data. The new system also enables the reuse of processed cytometry data, the integration of population counts identified by manual gating to increase the value of the data, and allowing for cross-project analysis.
With new unbiased analysis features and an easy-to-use interface, the CytoML 5.2 uses a batch processing tool to engage a range of parameters used simultaneously to aid scientists in finding the best representation of their data. After significant clusters have been pinpointed, these clusters can be overlaid with marker expression and many types of meta-data to drive hypothesis testing. Meanwhile, the unbiased analysis features simplify the process of assigning identities to populations from clustering outputs.
“Unbiased analysis tools allow complex multi-dimensional data to be simplified, unified, processed, and visualized so that it can be more easily explored and compared,” said Satnam Surae, chief product officer at Aigenpulse, in an April 27, 2021 company press release. “This kind of analysis can be very useful in exploring data without any prior assumptions, as a means to uncover novel insights. It is a complementary technique to semi-automated approaches and is interoperable within the CytoML 5.2 Suite, enabling comparison and validation.”
Source: Aigenpulse
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.